10/521,508 YONG CHU 04-03-2006

$%^STN;HighlightOn=;**HighlightOff=**;

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptaylc1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	DEC 21	IPC search and display fields enhanced in CA/CAplus with the IPC reform
NEWS 4	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/ USPAT2
NEWS 5	JAN 13	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 6	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS 7	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS 8	JAN 17	IPC 8 in the WPI family of databases including WPIFV
NEWS 9	JAN 30	Saved answer limit increased
NEWS 10	JAN 31	Monthly current-awareness alert (SDI) frequency added to TULSA
NEWS 11	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS 12	FEB 22	Status of current WO (PCT) information on STN
NEWS 13	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS 14	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS 15	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS 16	FEB 28	MEDLINE/LMEDLINE reload improves functionality
NEWS 17	FEB 28	TOXCENTER reloaded with enhancements
NEWS 18	FEB 28	REGISTRY/ZREGISTRY enhanced with more experimental spectral property data
NEWS 19	MAR 01	INSPEC reloaded and enhanced
NEWS 20	MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS 21	MAR 08	X.25 communication option no longer available after June 2006
NEWS 22	MAR 22	EMBASE is now updated on a daily basis
NEWS 23	APR 03	New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS 24	APR 03	Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT
http://download.cas.org/express/v8.0-Discover/

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:19:28 ON 03 APR 2006

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.89	1.89

FILE 'REGISTRY' ENTERED AT 15:24:51 ON 03 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 2 APR 2006 HIGHEST RN 878996-50-0
DICTIONARY FILE UPDATES: 2 APR 2006 HIGHEST RN 878996-50-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10521508\10521508c.str





chain nodes :
6 7 8 9 10 11 12 13 17 18 19
ring nodes :
1 2 3 4 5
chain bonds :
1-6 2-8 3-7 7-9 8-13 9-10 10-11 10-12 13-17 17-18 18-19
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-2 1-5 1-6 2-3 3-4 4-5 7-9 10-12 13-17
exact bonds :
2-8 3-7 8-13 9-10 10-11 17-18 18-19

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 17:CLASS 18:CLASS 19:CLASS

L1 STRUCTURE UPLOADED

=> s
ENTER LOGIC EXPRESSION, QUERY NAME, OR (END):end
SEARCH ENDED BY USER

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 15:25:32 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 4 TO ITERATE

100.0% PROCESSED 4 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 4 TO 200
PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 15:25:45 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 85 TO ITERATE

100.0% PROCESSED 85 ITERATIONS 54 ANSWERS
SEARCH TIME: 00.00.01

L3 54 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 167.38 169.27

FILE 'CAPLUS' ENTERED AT 15:26:00 ON 03 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 3 Apr 2006 VOL 144 ISS 15
FILE LAST UPDATED: 2 Apr 2006 (20060402/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4 3 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:203664 CAPLUS
DOCUMENT NUMBER: 140:253553
TITLE: Preparation of oxazolidin-2-one and thiazolidin-2-one derivatives for use as prostaglandin E2 receptor EP4-subtype agonists
INVENTOR(S): Han, Yongxin; Colucci, John; Billot, Xavier; Wilson, Marie-Claire; Young, Robert
PATENT ASSIGNEE(S): Merck Frosst Canada & Co., Can.
SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004019938	A1	20040311	WO 2003-CA1306	20030825
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2495917	AA	20040311	CA 2003-2495917	20030825
AU 2003258433	A1	20040319	AU 2003-258433	20030825
EP 1545517	A1	20050629	EP 2003-790594	20030825
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006504679	T2	20060209	JP 2004-531332	20030825
PRIORITY APPLN. INFO.:			US 2002-406530P	P 20020828
			WO 2003-CA1306	W 20030825

OTHER SOURCE(S): MARPAT 140:253553
GI



I

AB This invention relates to compds. of formula (I) [X = O, S; Y] = CH2CH2, CH:CH, cyclopropane-1,2-diyl; Y = CO, CH(OH); A, W = a bond, C1-6 alkylene
optionally substituted with 1, 2, 3, or 4 halogen atoms; Z = O, S, cyclopropane-1,2-diyl, CH2, HC:H, C.tplbond.C, each disubstituted aryl or heteroaryl ring; R2 = C1-6 alkyl, provided that R2 is not n-pentyl,

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 670220-30-1 CAPLUS
CN 3-Thiazolidineheptanenitrile, 2-oxo-4-[(1E)-3-oxo-4-phenyl-1-butenyl]-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 670220-31-2 CAPLUS
CN 3-Thiazolidineheptanenitrile, 4-[(1E)-3-hydroxy-4-phenyl-1-butenyl]-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 670219-01-9P, 7-[4-((1E)-4,4-Difluoro-3-hydroxy-4-phenylbut-1-enyl)-2-oxo-1,3-thiazolidin-3-yl]heptanoic acid 670219-02-0P, 7-[4-((1E)-3-Hydroxy-4-phenylbut-1-enyl)-2-oxo-1,3-thiazolidin-3-yl]heptanoic acid 670219-03-1P, 4-((1E)-4,4-Difluoro-3-hydroxy-4-phenylbut-1-enyl)-3-[6-(1H-tetrazol-5-yl)hexyl]-1,3-thiazolidin-2-one 670219-04-2P, 4-((1E)-3-Hydroxy-4-phenylbut-1-enyl)-3-[6-(1H-tetrazol-5-yl)hexyl]-1,3-thiazolidin-2-one 670219-06-4P,

4-(3-Hydroxy-4-phenylbutyl)-3-[6-(1H-tetrazol-5-yl)hexyl]-1,3-thiazolidin-2-one 670219-07-5P, 4-(4,4-Difluoro-3-hydroxy-4-phenylbutyl)-3-[6-(1H-tetrazol-5-yl)hexyl]-1,3-thiazolidin-2-one 670219-08-6P,

7-[4-[(1E)-4,4-Difluoro-3-hydroxy-4-[3-(methoxymethyl)phenyl]but-1-enyl]-2-oxo-1,3-thiazolidin-3-yl]heptanoic acid 670219-09-7P,

4-[(1E)-4,4-Difluoro-3-hydroxy-4-[3-(methoxymethyl)phenyl]but-1-enyl]-3-[6-

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(CH2)0-8-C6-10 aryl, (CH2)0-8-C5-10 heteroaryl, (CH2)0-8-C3-10 heterocycloalkyl, (CH2)0-8-C3-8cycloalkyl, O-C1-10-oalkyl, O-C6-10aryl, O-C5-10heteroaryl, O-C5-10heterocycloalkyl, O-C3-10cycloalkyl wherein aryl, heteroaryl, heterocycloalkyl, and cycloalkyl are optionally substituted; R3, R4 = H, halogen, C1-6 alkyl; or R3 and R4, together with the carbon atom to which they are attached, form a C3-7 cycloalkyl ring; R5 = H, OH, CH2OH, C1-6 alkoxy, NHPO2R6, NHR9, NHSO2R8, NR6R7; R6, R7 = H,
C1-6 alkyl; R8 = H, C6-10 aryl, C1-4 alkyl; R9 = acyl, sulfonyl] are prepd. These compds. are potent selective agonists of the EP4 subtype of prostaglandin E2 receptors. Also disclosed are their use for a medicament
in the treatment of conditions which are related to elevated intraocular pressure in the eye of a patient by (1) treating ocular hypertension, glaucoma, macular edema, or macular degeneration, (2) increasing retinal and optic nerve head blood velocity, (3) increasing retinal and optic nerve tension, (4) providing a neuroprotective effect, or (5) treating dry
eyes.

IT 670220-25-4P, Ethyl 7-[(4S)-2-oxo-4-[(1E)-3-oxo-4-phenylbut-1-enyl]-1,3-thiazolidin-3-yl]heptanoate 670220-26-5P, Ethyl 7-[(4S)-4-((1E)-3-hydroxy-4-phenylbut-1-enyl)-2-oxo-1,3-thiazolidin-3-yl]heptanoate 670220-30-1P, 7-[(4S)-2-Oxo-4-((1E)-3-oxo-4-phenylbut-1-enyl)-1,3-thiazolidin-3-yl]heptanenitrile 670220-31-2P, 7-[(4S)-4-((1E)-3-Hydroxy-4-phenylbut-1-enyl)-2-oxo-1,3-thiazolidin-3-yl]heptanenitrile
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of oxazolidinone and thiazolidinone derivs. as
prostaglandin E2 receptor EP4-subtype agonists in treatment of conditions related to elevated intraocular pressure in eye)

RN 670220-25-4 CAPLUS
CN 3-Thiazolidineheptanoic acid, 2-oxo-4-[(1E)-3-oxo-4-phenyl-1-butenyl]-, ethyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 670220-26-5 CAPLUS
CN 3-Thiazolidineheptanoic acid, 4-[(1E)-3-hydroxy-4-phenyl-1-butenyl]-2-oxo-, ethyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(1H-tetrazol-5-yl)hexyl]-1,3-thiazolidin-2-one 670219-10-0P,

4-((1E)-4-Cyclohexyl-4,4-difluoro-3-hydroxybut-1-enyl)-3-[6-(1H-tetrazol-5-yl)hexyl]-1,3-thiazolidin-2-one 670219-11-1P, 4-((1E)-4-Cyclohexyl-3-hydroxybut-1-enyl)-3-[6-(1H-tetrazol-5-yl)hexyl]-1,3-thiazolidin-2-one 670219-12-2P, 4-(4,4-Difluoro-3-oxo-4-phenylbutyl)-3-[6-(1H-tetrazol-5-yl)hexyl]-1,3-thiazolidin-2-one 670219-13-3P, 4-(3-Oxo-4-phenylbutyl)-3-[6-(1H-tetrazol-5-yl)hexyl]-1,3-thiazolidin-2-one 670219-16-6P, 4-((1E)-4,4-Difluoro-3-hydroxy-4-phenylbut-1-enyl)-3-(7-hydroxy-6-oxoheptyl)-1,3-thiazolidin-2-one 670219-17-7P,

4-((1E)-4,4-Difluoro-3-hydroxy-4-phenylbut-1-enyl)-3-[(2E)-6-(1H-tetrazol-5-yl)hex-2-enyl]-1,3-thiazolidin-2-one 670219-18-8P,

4-((1E)-4,4-Difluoro-3-hydroxy-4-phenylbut-1-enyl)-3-[(3E)-6-(1H-tetrazol-5-yl)hex-3-enyl]-1,3-thiazolidin-2-one 670219-19-9P,

4-((1E)-4,4-Difluoro-3-hydroxy-4-phenylbut-1-enyl)-3-[(4E)-6-(1H-tetrazol-5-yl)hex-4-enyl]-1,3-thiazolidin-2-one 670219-20-2P,

4-((1E)-4,4-Difluoro-3-hydroxy-4-phenylbut-1-enyl)-3-[(2Z)-6-(1H-tetrazol-5-yl)hex-2-enyl]-1,3-thiazolidin-2-one 670219-21-3P,

4-((1E)-4,4-Difluoro-3-hydroxy-4-phenylbut-1-enyl)-3-[(3Z)-6-(1H-tetrazol-5-yl)hex-3-enyl]-1,3-thiazolidin-2-one 670219-22-4P,

4-((1E)-4,4-Difluoro-3-hydroxy-4-phenylbut-1-enyl)-3-[(4Z)-6-(1H-tetrazol-5-yl)hex-4-enyl]-1,3-thiazolidin-2-one 670219-23-5P,

4-((1E)-4,4-Difluoro-3-hydroxy-4-phenylbut-1-enyl)-3-[6-(1H-tetrazol-5-yl)-4-hexyn-1-yl]-1,3-thiazolidin-2-one 670219-24-6P 670219-25-7P, 4-((1E)-4,4-Difluoro-3-hydroxy-4-phenylbut-1-enyl)-3-[6-(1H-tetrazol-5-yl)-3-hexyn-1-yl]-1,3-thiazolidin-2-one 670219-26-8P, 5-[3-[4-((1E)-4,4-Difluoro-3-hydroxy-4-phenylbut-1-enyl)-2-oxo-1,3-thiazolidin-3-yl]propyl]thiophene-2-carboxylic acid 670219-27-9P, 5-[3-[4-((1E)-4,4-Difluoro-3-hydroxy-4-phenylbut-1-enyl)-2-oxo-1,3-thiazolidin-3-yl]propyl]-2-furoic acid 670219-28-0P, 4-((1E)-4,4-Difluoro-3-hydroxy-4-phenylbut-1-enyl)-3-[3-[5-(1H-tetrazol-5-yl)-2-furyl]propyl]-1,3-thiazolidin-2-one 670219-29-1P, 4-((1E)-4,4-Difluoro-3-hydroxy-4-phenylbut-1-enyl)-3-[3-[5-(1H-tetrazol-5-yl)thien-2-yl]propyl]-1,3-thiazolidin-2-one 670219-34-6P, 3-[3-[4-((1E)-4,4-Difluoro-3-hydroxy-4-phenylbut-1-enyl)-2-oxo-1,3-thiazolidin-3-yl]propyl]benzoic acid 670219-35-9P, 4-[3-[4-((1E)-4,4-Difluoro-3-hydroxy-4-phenylbut-1-enyl)-2-oxo-1,3-thiazolidin-3-yl]propyl]benzoic acid 670219-36-0P, 2-[3-[4-((1E)-4,4-Difluoro-3-hydroxy-4-phenylbut-1-enyl)-2-oxo-1,3-thiazolidin-3-yl]propyl]benzoic acid 670219-37-1P,

4-((1E)-4,4-Difluoro-3-hydroxy-4-phenylbut-1-enyl)-3-[3-(3-(1H-tetrazol-5-yl)phenyl]propyl]-1,3-thiazolidin-2-one 670219-38-2P,

4-((1E)-4,4-Difluoro-3-hydroxy-4-phenylbut-1-enyl)-3-[3-[2-(1H-tetrazol-5-yl)phenyl]propyl]-1,3-thiazolidin-2-one 670219-39-3P,

4-((1E)-4,4-Difluoro-3-hydroxy-4-phenylbut-1-enyl)-3-[3-[4-(1H-tetrazol-5-yl)phenyl]propyl]-1,3-thiazolidin-2-one 670219-43-9P, 7-[4-((1E)-4,4-Difluoro-3-hydroxy-4-phenylbut-1-enyl)-2-oxo-1,3-thiazolidin-3-yl]-2,2-difluoroheptanoic acid 670219-44-0P, 7-[4-((1E)-4,4-Difluoro-3-hydroxy-4-phenylbut-1-enyl)-2-oxo-1,3-

thiazolidin-3-yl]-4,4-difluoroheptanoic acid **670219-45-1P**,
7-[4-((1E)-4,4-Difluoro-3-hydroxy-4-phenylbut-1-enyl)-2-oxo-1,3-thiazolidin-3-yl]-5,5-difluoroheptanoic acid **670219-46-2P**,
7-[4-((1E)-4,4-Difluoro-3-hydroxy-4-phenylbut-1-enyl)-2-oxo-1,3-thiazolidin-3-yl]-6,6-difluoroheptanoic acid **670219-48-4P**,
3-[3-[4-((1E)-4,4-Difluoro-3-hydroxy-4-phenylbut-1-enyl)-2-oxo-1,3-thiazolidin-3-yl]propoxy]propanoic acid **670219-49-5P**,
[4-[4-((1E)-4,4-Difluoro-3-hydroxy-4-phenylbut-1-enyl)-2-oxo-1,3-thiazolidin-3-yl]butoxy]acetic acid **670219-50-8P**,
[[4-[4-((1E)-4,4-Difluoro-3-hydroxy-4-phenylbut-1-enyl)-2-oxo-1,3-thiazolidin-3-yl]butyl]thio]acetic acid **670219-51-9P**,
3-[[3-[4-((1E)-4,4-Difluoro-3-hydroxy-4-phenylbut-1-enyl)-2-oxo-1,3-thiazolidin-3-yl]propyl]thio]propanoic acid **670220-22-1P**
670220-27-6P, (4S)-4-((1E)-3-Hydroxy-4-phenylbut-1-enyl)-3-[6-(1H-tetrazol-5-yl)hexyl]-1,3-thiazolidin-2-one
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of oxazolidinone and thiazolidinone derivs. as prostaglandin E2
receptor EP4-subtype agonists in treatment of conditions related to elevated intraocular pressure in eye)

RN 670219-01-9 CAPLUS
CN 3-Thiazolidineheptanoic acid, 4-[(1E)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]-2-oxo- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 670219-02-0 CAPLUS
CN 3-Thiazolidineheptanoic acid, 4-[(1E)-3-hydroxy-4-phenyl-1-butenyl]-2-oxo- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 670219-03-1 CAPLUS
CN 2-Thiazolidinone, 4-[(1E)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]-3-[6-(1H-tetrazol-5-yl)hexyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 670219-08-6 CAPLUS
CN 3-Thiazolidineheptanoic acid, 4-[(1E)-4,4-difluoro-3-hydroxy-4-[3-(methoxymethyl)phenyl]-1-butenyl]-2-oxo- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 670219-09-7 CAPLUS
CN 2-Thiazolidinone, 4-[(1E)-4,4-difluoro-3-hydroxy-4-[3-(methoxymethyl)phenyl]-1-butenyl]-3-[6-(1H-tetrazol-5-yl)hexyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 670219-10-0 CAPLUS
CN 2-Thiazolidinone, 4-[(1E)-4-cyclohexyl-4,4-difluoro-3-hydroxy-1-butenyl]-3-[6-(1H-tetrazol-5-yl)hexyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 670219-04-2 CAPLUS
CN 2-Thiazolidinone, 4-[(1E)-3-hydroxy-4-phenyl-1-butenyl]-3-[6-(1H-tetrazol-5-yl)hexyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 670219-06-4 CAPLUS
CN 2-Thiazolidinone, 4-(3-hydroxy-4-phenylbutyl)-3-[6-(1H-tetrazol-5-yl)hexyl]- (9CI) (CA INDEX NAME)



RN 670219-07-5 CAPLUS
CN 2-Thiazolidinone, 4-(4,4-difluoro-3-hydroxy-4-phenylbutyl)-3-[6-(1H-tetrazol-5-yl)hexyl]- (9CI) (CA INDEX NAME)



RN 670219-11-1 CAPLUS
CN 2-Thiazolidinone, 4-[(1E)-4-cyclohexyl-3-hydroxy-1-butenyl]-3-[6-(1H-tetrazol-5-yl)hexyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 670219-12-2 CAPLUS
CN 2-Thiazolidinone, 4-(4,4-difluoro-3-oxo-4-phenylbutyl)-3-[6-(1H-tetrazol-5-yl)hexyl]- (9CI) (CA INDEX NAME)



RN 670219-13-3 CAPLUS
CN 2-Thiazolidinone, 4-(3-oxo-4-phenylbutyl)-3-[6-(1H-tetrazol-5-yl)hexyl]- (9CI) (CA INDEX NAME)



RN 670219-16-6 CAPLUS
CN 2-Thiazolidinone, 4-[(1E)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]-3-(7-hydroxy-6-oxoheptyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 670219-17-7 CAPLUS
CN 2-Thiazolidinone, 4-[(1E)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]-3-[(2E)-6-(1H-tetrazol-5-yl)-2-hexenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 670219-18-8 CAPLUS
CN 2-Thiazolidinone, 4-[(1E)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]-3-[(3E)-6-(1H-tetrazol-5-yl)-3-hexenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 670219-19-9 CAPLUS
CN 2-Thiazolidinone, 4-[(1E)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]-3-[(4E)-6-(1H-tetrazol-5-yl)-4-hexenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 670219-20-2 CAPLUS
CN 2-Thiazolidinone, 4-[(1E)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]-3-[(2Z)-6-(1H-tetrazol-5-yl)-2-hexenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 670219-21-3 CAPLUS
CN 2-Thiazolidinone, 4-[(1E)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]-3-[(3Z)-6-(1H-tetrazol-5-yl)-3-hexenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 670219-22-4 CAPLUS
CN 2-Thiazolidinone, 4-[(1E)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]-3-[(4Z)-6-(1H-tetrazol-5-yl)-4-hexenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 670219-23-5 CAPLUS
CN 2-Thiazolidinone, 4-[(1E)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]-3-[6-(1H-tetrazol-5-yl)-4-hexynyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 670219-24-6 CAPLUS
CN 2-Thiazolidinone, 4-[(1E)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]-3-[6-(1H-tetrazol-5-yl)-2-hexynyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 670219-25-7 CAPLUS
CN 2-Thiazolidinone, 4-[(1E)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]-3-[6-(1H-tetrazol-5-yl)-3-hexynyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 670219-26-8 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-[3-[4-[(1E)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]-2-oxo-3-thiazolidinyl]propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 670219-27-9 CAPLUS
CN 2-Furancarboxylic acid, 5-[3-[4-[(1E)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]-2-oxo-3-thiazolidinyl]propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 670219-28-0 CAPLUS
CN 2-Thiazolidinone,
4-[(1E)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]-3-[3-[5-(1H-tetrazol-5-yl)-2-furanyl]propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 670219-29-1 CAPLUS
CN 2-Thiazolidinone,
4-[(1E)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]-3-[3-[5-(1H-tetrazol-5-yl)-2-thienyl]propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 670219-34-8 CAPLUS
CN Benzoic acid, 3-[3-[4-[(1E)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]-2-oxo-3-thiazolidinyl]propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 670219-38-2 CAPLUS
CN 2-Thiazolidinone,
4-[(1E)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]-3-[3-[2-(1H-tetrazol-5-yl)phenyl]propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 670219-39-3 CAPLUS
CN 2-Thiazolidinone,
4-[(1E)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]-3-[3-[4-(1H-tetrazol-5-yl)phenyl]propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.





RN 670219-35-9 CAPLUS
CN Benzoic acid, 4-[3-[4-[(1E)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]-2-oxo-3-thiazolidinyl]propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 670219-36-0 CAPLUS
CN Benzoic acid, 2-[3-[4-[(1E)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]-2-oxo-3-thiazolidinyl]propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 670219-37-1 CAPLUS
CN 2-Thiazolidinone,
4-[(1E)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]-3-[3-[3-(1H-tetrazol-5-yl)phenyl]propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 670219-43-9 CAPLUS
CN 3-Thiazolidineheptanoic acid, 4-[(1E)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]-α,α-difluoro-2-oxo- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 670219-44-0 CAPLUS
CN 3-Thiazolidineheptanoic acid, 4-[(1E)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]-γ,γ-difluoro-2-oxo- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 670219-45-1 CAPLUS
CN 3-Thiazolidineheptanoic acid, 4-[(1E)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]-δ,δ-difluoro-2-oxo- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 670219-46-2 CAPLUS
CN 3-Thiazolidineheptanoic acid, 4-[(1E)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]-ε,ε-difluoro-2-oxo- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 670219-48-4 CAPLUS
CN Propanoic acid,
3-[3-[4-[(1E)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]-2-oxo-3-thiazolidinyl]propoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 670219-49-5 CAPLUS
CN Acetic acid,
[4-[4-[(1E)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]-2-oxo-3-thiazolidinyl]butoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 670219-50-8 CAPLUS
CN Acetic acid,
[[4-[4-[(1E)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]-2-oxo-3-thiazolidinyl]butyl]thio]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 670219-51-9 CAPLUS
CN Propanoic acid,
3-[[3-[4-[(1E)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]-2-oxo-3-thiazolidinyl]propyl]thio]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 670220-22-1 CAPLUS
CN 3-Thiazolidineheptanoic acid,
4-[(1E)-3-hydroxy-4-phenyl-1-butenyl]-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 670220-27-6 CAPLUS
CN 2-Thiazolidinone,
4-[(1E)-3-hydroxy-4-phenyl-1-butenyl]-3-[6-(1H-tetrazol-5-yl)hexyl]-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1984:103049 CAPLUS
DOCUMENT NUMBER: 100:103049
TITLE: Prostaglandin derivatives
PATENT ASSIGNEE(S): Chugai Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 58150575	A2	19830907	JP 1982-32987	19820304
PRIORITY APPLN. INFO.:			JP 1982-32987	19820304

GI



I

III



IV

V



VI

AB Prostaglandin derivs. I (Z = O, S) were prepared starting with HZCH2CH(NH2)CO2Et (II) in 7-9 steps. Thus, cyclization of D-II (Z = S) with COCl2 gave III, which was reduced and treated with H2C:CHOEt to give IV. Condensation of IV with I(CH2)6CO2Et followed by deprotection and oxidation gave V. Wittig reaction of V with (MeO)2P(O)CH2OC5H11, reduction of the resulting VI, and hydrolysis gave (12S,15S)-(+)-I and (12S,15R)-(+)-I (Z = S).

IT **82430-19-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrolysis of)

RN 82430-19-1 CAPLUS

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 3-Thiazolidineheptanoic acid, 2-oxo-4-(3-oxo-1-octenyl)-, ethyl ester, [S-(E)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT **82430-23-7P 82430-24-8P 82430-25-9P**
82430-26-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 82430-23-7 CAPLUS
CN 3-Thiazolidineheptanoic acid, 4-(3-hydroxy-1-octenyl)-2-oxo-, [S-[R*,R*-(E)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 82430-24-8 CAPLUS
CN 3-Thiazolidineheptanoic acid, 4-(3-hydroxy-1-octenyl)-2-oxo-, [R-[R*,S*-(E)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 82430-25-9 CAPLUS
CN 3-Thiazolidineheptanoic acid, 4-(3-hydroxy-1-octenyl)-2-oxo-, [R-[R*,R*-(E)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 82430-26-0 CAPLUS
CN 3-Thiazolidineheptanoic acid, 4-(3-hydroxy-1-octenyl)-2-oxo-, [S-[R*,S*-(E)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1982:455523 CAPLUS
DOCUMENT NUMBER: 97:55523
TITLE: Synthesis of both enantiomers of 8-aza-11-deoxy-10-thiaprostaglandin E1
AUTHOR(S): Kubodera, Noboru; Nagano, Hiroyuki; Takagi, Michiro; Matsunaga, Isao
CORPORATE SOURCE: New Drug Res. Lab., Chugai Pharm. Co., Ltd., Tokyo, 171, Japan
SOURCE: Heterocycles (1982), 18(Spec. Issue), 259-63
CODEN: HTCYAM; ISSN: 0385-5414
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB I and its 15β epimer were prepad. from D-cysteine via cyclization of the Et ester-HCl with COCl2, reduction with NaBH4 to give (S)-II, and conventional alkylation, etc. The enantiomers of I and 15β-I were similarly prepared from L-cysteine.

IT **82430-19-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and borohydride reduction of)
RN 82430-19-1 CAPLUS
CN 3-Thiazolidineheptanoic acid, 2-oxo-4-(3-oxo-1-octenyl)-, ethyl ester, [S-(E)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT **82430-20-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and conformation and configuration of)
RN 82430-20-4 CAPLUS
CN 3-Thiazolidineheptanoic acid, 4-(3-hydroxy-1-octenyl)-2-oxo-, ethyl ester,
[S-[R*,R*-(E)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Double bond geometry as shown.



IT **82430-22-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and ozonolysis of)
RN 82430-22-6 CAPLUS
CN 3-Thiazolidineheptanoic acid, 4-[3-(acetyloxy)-1-octenyl]-2-oxo-, ethyl ester, [S-[R*,R*-(E)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT **82430-21-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and saponification of)
RN 82430-21-5 CAPLUS
CN 3-Thiazolidineheptanoic acid, 4-(3-hydroxy-1-octenyl)-2-oxo-, ethyl ester,
[R-[R*,S*-(E)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT **82430-23-7P 82430-24-8P 82430-25-9P 82430-26-0P**

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RL: RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of, from cysteine)
RN 82430-23-7 CAPLUS
CN 3-Thiazolidineheptanoic acid, 4-(3-hydroxy-1-octenyl)-2-oxo-, [S-[R*,R*-(E)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 82430-24-8 CAPLUS
CN 3-Thiazolidineheptanoic acid, 4-(3-hydroxy-1-octenyl)-2-oxo-, [R-[R*,S*-(E)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 82430-25-9 CAPLUS
CN 3-Thiazolidineheptanoic acid, 4-(3-hydroxy-1-octenyl)-2-oxo-, [R-[R*,R*-(E)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 82430-26-0 CAPLUS
CN 3-Thiazolidineheptanoic acid, 4-(3-hydroxy-1-octenyl)-2-oxo-, [S-[R*,S*-(E)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


CO2H
(CH2)6
OH
N
E
O
R
S
S
(CH2)4
Me